title: Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome.
abstract: Important sources of metabolic diseases such as obesity and metabolic syndrome are significantly more prevalent in patients treated with antipsychotic drugs than the general population and they not only reduce the quality of life but also significantly reduce the life expectancy, being important risk factors for cardiovascular disease. The pathogenic mechanisms underlying these events are not entirely clear they are complex and multi-determined or not tied to a single defining event. In this review we examine the literature on the interactions of antipsychotic drugs with neurotransmitters in the brain, with pharmacogenetics hormones and peripheral mechanisms that may induce, albeit in different ways between different molecules, not only weight gain but also 'onset of major diseases such as diabetes, dyslipidemia and hypertension that are the basis of the metabolic syndrome. Today, the possible metabolic changes induced by various antipsychotic drugs and their major physical health consequences, are among the major concerns of clinicians and it is therefore necessary to monitor the main metabolic parameters to prevent or minimize any of these patients as well as the metabolism events associated with the use of antipsychotic drugs.
authors.affiliation: Mental Health Unit- District 24 - ASL Napoli 1 Center, Italy.
authors.forename: Walter
authors.initials: W
authors.lastname: Milano
authors.forename: Michele
authors.initials: M
authors.lastname: De Rosa
authors.forename: Luca
authors.initials: L
authors.lastname: Milano
authors.forename: Anna
authors.initials: A
authors.lastname: Capasso
keywords: Antipsychotic drugs; metabolic risk; weight gain.
references.citation: Am J Psychiatry. 2007 Jul;164(7):1050-60
references.pmid: 17606657
references.citation: Lancet. 2005 Sep 24-30;366(9491):1059-62
references.pmid: 16182882
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):1-4
references.pmid: 19922755
references.citation: Lancet. 2005 Oct 1;366(9492):1197-209
references.pmid: 16198769
references.citation: Psychiatr Clin North Am. 2009 Dec;32(4):775-94
references.pmid: 19944883
references.citation: Curr Drug Targets. 2006 Dec;7(12):1681-95
references.pmid: 17168843
references.citation: CNS Drugs. 2005;19 Suppl 1:1-93
references.pmid: 15998156
references.citation: J Clin Psychiatry. 2004 Feb;65(2):267-72
references.pmid: 15003083
references.citation: Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):460-6
references.pmid: 20717020
references.citation: Schizophr Res. 2009 Jun;111(1-3):9-16
references.pmid: 19398192
references.citation: JAMA. 2001 May 16;285(19):2486-97
references.pmid: 11368702
references.citation: CNS Drugs. 2008;22(7):547-62
references.pmid: 18547125
references.citation: Schizophr Bull. 2008 Jan;34(1):60-71
references.pmid: 17923452
references.citation: Int J Obes (Lond). 2006 Mar;30(3):520-7
references.pmid: 16302014
references.citation: Arch Gen Psychiatry. 2007 Oct;64(10):1123-31
references.pmid: 17909124
references.citation: Rev Recent Clin Trials. 2011 Jan;6(1):52-63
references.pmid: 20868350
references.citation: J Clin Psychopharmacol. 2002 Aug;22(4):424-6
references.pmid: 12172344
references.citation: Obes Rev. 2009 Sep;10(5):527-42
references.pmid: 19460111
references.citation: Med Clin North Am. 2004 Sep;88(5):1273-94
references.pmid: 15331317
references.citation: J Clin Psychopharmacol. 2007 Feb;27(1):46-51
references.pmid: 17224711
references.citation: N Engl J Med. 2005 Sep 22;353(12):1209-23
references.pmid: 16172203
references.citation: Acta Psychiatr Scand. 2009 Jan;119(1):4-14
references.pmid: 19133915
references.citation: Clin Chem. 2004 Sep;50(9):1511-25
references.pmid: 15265818
references.citation: Arch Gen Psychiatry. 2007 Feb;64(2):242-9
references.pmid: 17283292
references.citation: J Psychopharmacol. 2007 Sep;21(7):728-34
references.pmid: 17092963
references.citation: J Clin Psychiatry. 2004;65 Suppl 18:47-56
references.pmid: 15600384
references.citation: Pharmacogenomics J. 2010 Feb;10(1):30-9
references.pmid: 19918262
references.citation: Lancet. 2009 Jan 3;373(9657):31-41
references.pmid: 19058842
references.citation: Pharmacol Ther. 2010 Jan;125(1):169-79
references.pmid: 19931306
references.citation: Br J Psychiatry. 2004 Jan;184:58-62
references.pmid: 14702228
references.citation: Psychopharmacol Bull. 2007;40(1):57-62
references.pmid: 17285096
references.citation: Pharmacogenomics. 2006 Sep;7(6):863-87
references.pmid: 16981847
references.citation: Diabetes Obes Metab. 2009 Jul;11(7):665-79
references.pmid: 19476478
references.citation: J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):687-700
references.pmid: 17513981
references.citation: Psychoneuroendocrinology. 2008 Jun;33(5):569-80
references.pmid: 18358632
references.citation: Pharmacogenet Genomics. 2005 Apr;15(4):195-200
references.pmid: 15864111
references.citation: Obes Rev. 2004 Aug;5(3):167-70
references.pmid: 15245385
references.citation: J Psychopharmacol. 2006 Jul;20(4 Suppl):15-8
references.pmid: 16785265
references.citation: Diabetes. 2002 Oct;51(10):3120-7
references.pmid: 12351457
references.citation: J Psychiatr Res. 2003 May-Jun;37(3):193-220
references.pmid: 12650740
references.citation: JAMA. 2002 Dec 4;288(21):2709-16
references.pmid: 12460094
references.citation: Acta Psychiatr Scand. 2006 Apr;113(4):306-13
references.pmid: 16638075
references.citation: Circulation. 2005 Mar 22;111(11):1448-54
references.pmid: 15781756
references.citation: Psychoneuroendocrinology. 2005 Jan;30(1):106-10
references.pmid: 15358448
references.citation: Expert Rev Neurother. 2010 Jul;10(7):1175-200
references.pmid: 20586697
references.citation: Psychopharmacology (Berl). 2004 Aug;174(4):477-89
references.pmid: 15243737
references.citation: Aust N Z J Psychiatry. 2008 May;42(5):369-81
references.pmid: 18473255
references.citation: J Clin Psychopharmacol. 2007 Aug;27(4):338-43
references.pmid: 17632216
references.citation: Life Sci. 2004 Mar 5;74(16):1999-2008
references.pmid: 14967195
references.citation: World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
references.pmid: 11234459
references.citation: Pharmacopsychiatry. 2000 May;33(3):81-8
references.pmid: 10855458
references.citation: Neuroendocrinology. 2007;85(4):249-56
references.pmid: 17570902
references.citation: World Psychiatry. 2009 Feb;8(1):15-22
references.pmid: 19293950
references.citation: Schizophr Bull. 2008 Nov;34(6):1189-99
references.pmid: 18165262
references.citation: J Clin Psychiatry. 2008;69 Suppl 4:26-36
references.pmid: 18533766
references.citation: Neuropsychopharmacology. 2010 May;35(6):1315-24
references.pmid: 20107430